Achieving adequate control of cardiovascular risk in type 2 diabetes mellitus (DM) is crucially important; however, the atherogenic dyslipidaemia (including low high-density lipoprotein cholesterol and hypertriglyceridaemia) typically encountered in type 2 DM is often managed inadequately. Evidence from the Fenofibrate Intervention and Event Lowering in Diabetes study suggests that fenofibrate reduces the risk of long-term macrovascular and microvascular type 2 diabetic complications, especially in patients demonstrating features of the metabolic syndrome. Fenofibrate represents a useful treatment option for controlling cardiovascular risk in type 2 diabetes patients in the community setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1742-1241.2009.02053.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomised, multicentre, placebo-controlled trial of fenofibrate for treatment of diabetic macular oedema with economic evaluation (FORTE study): study protocol for a randomised control trial.
BMJ Open
December 2024
Westmead Institute for Medical Research, Westmead, New South Wales, Australia
Introduction: Diabetic macular oedema (DMO), a serious ocular complication of diabetic retinopathy (DR), is a leading cause of vision impairment worldwide. If left untreated or inadequately treated, DMO can lead to irreversible vision loss and blindness. Intravitreal injections using antivascular endothelial growth factor (anti-VEGF) and laser are the current standard of treatment for DMO.
View Article and Find Full Text PDFAliphatic substrates-mediated unique rapid room temperature synthesis of carbon quantum dots for fenofibrate versatile analysis.
Anal Chim Acta
February 2025
Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. Electronic address:
Background: The current synthetic strategies for carbon dots (CDs) are usually time-consuming, rely on complicated processes, and need high temperatures and energy. Recent studies have successfully synthesized CDs at room temperature. Unfortunately, most CDs synthesized at room temperature are obtained under harsh reaction conditions, prepared using aromatic precursors, or need a long time to generate.
View Article and Find Full Text PDFSustained-Release Solid Dispersions of Fenofibrate for Simultaneous Enhancement of the Extent and Duration of Drug Exposure.
Pharmaceutics
December 2024
College of Pharmacy, Dongguk University-Seoul, Dongguk-ro-32, Ilsan-Donggu, Goyang 10326, Republic of Korea.
Background/objectives: A sustained-release formulation of fenofibrate while enhancing drug dissolution with minimal food effect is critical for maximizing the therapeutic benefits of fenofibrate. Therefore, this study aimed to develop an effective solid dispersion formulation of fenofibrate for simultaneous enhancement in the extent and duration of drug exposure.
Methods: Fenofibrate-loaded solid dispersions (FNSDs) were prepared using poloxamer 407 and Eudragit RSPO at varied ratios via solvent evaporation.
Autoimmune hepatitis associated with statins: a retrospective study of pharmacovigilance databases and review of the literature.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Background: Statin-associated autoimmune hepatitis (AIH) is a rare but potentially life-threatening adverse event. Currently, no studies have investigated the association between AIH and different statins.
Research Design And Methods: This retrospective analysis of statin-associated AIH utilized the FDA Adverse Event Reporting System (FAERS) database (Q1 2004 to Q1 2024) and a systematic literature review.
Fenofibrate Inhibits LPS and Zymosan-induced Inflammatory Responses through Sonic Hedgehog in IMG Cells.
Curr Mol Pharmacol
January 2025
Department of Biochemistry, School of Medicine, China Medical University, Taichung, Taiwan.
Background: Neuroinflammatory responses are strongly associated with the pathogenesis of progressive neurodegenerative conditions and mood disorders. Modulating microglial activation is a potential strategy for developing protective treatments for central nervous system (CNS)-related diseases. Fibrates, widely used in clinical practice as cholesterol-lowering medications, exhibit numerous biological activities, such as anticancer and antiinflammatory activities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!